Pharma stocks plunged after President Trump announced potential tariffs on imported medicines, impacting Indian drugmakers significantly. India, a major medicine supplier to the U.S. with $12.72 billion in exports in 2024, faces challenges. Experts warn that tariffs could raise production costs and reduce competitiveness for Indian firms, despite their crucial role in the U.S. healthcare system.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets